Publications

This SWG was established in January 2024. Publications will be added in due course.

Highlights from the SWG

This SWG was established in January 2024. Highlights will be added in due course.

SWG educational activities

This SWG was established in January 2024. Educational activities will be added in due course.

SWG Educational Activities

TBA

Highlights from the SWG

TBA

SWG framework

Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.

Urgent actions are needed now to prevent a collapse of diagnostic testing.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Promising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013

What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.